ASCO 2006 highlights: Targeted therapy for renal cell carcinoma
- 30 June 2007
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 33 (4), 381-390
- https://doi.org/10.1016/j.ctrv.2007.01.002
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitorsMolecular Cancer Therapeutics, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Targeted agents for the treatment of advanced renal cell carcinomaCancer, 2005
- Raf: A Strategic Target for Therapeutic Development Against CancerJournal of Clinical Oncology, 2005
- Novel approaches in the therapy of metastatic renal cell carcinomaWorld Journal of Urology, 2005
- Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal CarcinomaClinical Cancer Research, 2004
- Epidermal Growth Factor Receptor and Epidermal Growth Factor Receptor Therapies in Renal Cell Carcinoma: Do We Need a Better Mouse Trap?Journal of Clinical Oncology, 2004
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003